Sofosbuvir/velpatasvir
Sofosbuvir/Velpatasvir
Sofosbuvir/Velpatasvir (pronunciation: soh-fohs-BYOO-vihr/vel-PAT-ahs-vihr) is a fixed-dose combination medication used for the treatment of chronic hepatitis C infection. It contains two antiviral drugs: sofosbuvir and velpatasvir.
Etymology
The name "Sofosbuvir" is derived from its chemical structure, which is a uridine nucleotide analog. "Velpatasvir" is named for its chemical structure as well, which is an NS5A inhibitor.
Usage
Sofosbuvir/Velpatasvir is used to treat all six major forms of hepatitis C, genotypes 1-6. It is taken orally once daily, typically for a course of 12 weeks.
Mechanism of Action
Sofosbuvir is a prodrug that is metabolized in the liver to its active form, which inhibits the hepatitis C virus (HCV) NS5B protein, a RNA-dependent RNA polymerase essential for viral replication. Velpatasvir is an inhibitor of the HCV NS5A protein, which is also involved in viral replication.
Side Effects
Common side effects of Sofosbuvir/Velpatasvir include headache, fatigue, nausea, insomnia, and anemia. Severe side effects may include reactivation of hepatitis B in those previously infected.
Related Terms
External links
- Medical encyclopedia article on Sofosbuvir/velpatasvir
- Wikipedia's article - Sofosbuvir/velpatasvir
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski